array:25 [
  "pii" => "S2013251421001085"
  "issn" => "20132514"
  "doi" => "10.1016/j.nefroe.2021.11.003"
  "estado" => "S300"
  "fechaPublicacion" => "2021-09-01"
  "aid" => "835"
  "copyright" => "Sociedad Española de Nefrología"
  "copyrightAnyo" => "2021"
  "documento" => "simple-article"
  "crossmark" => 0
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "cor"
  "cita" => "Nefrologia (English Version). 2021;41:601-3"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S0211699521000230"
      "issn" => "02116995"
      "doi" => "10.1016/j.nefro.2020.11.010"
      "estado" => "S300"
      "fechaPublicacion" => "2021-09-01"
      "aid" => "835"
      "copyright" => "Sociedad Española de Nefrología"
      "documento" => "simple-article"
      "crossmark" => 0
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "cor"
      "cita" => "Nefrologia. 2021;41:601-3"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Cartas al Director</span>"
        "titulo" => "Dosis &#250;nica de rituximab como tratamiento de recidiva de glomerulonefritis membranoproliferativa en trasplante renal"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "601"
            "paginaFinal" => "603"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Single rituximab dose as treatment for membranoproliferative glomerulonephritis relapse after kidney transplant"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1786
                "Ancho" => 2833
                "Tamanyo" => 225208
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Evoluci&#243;n de proteinuria y alb&#250;mina plasm&#225;tica&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Leonidas Cruzado Vega, Alba Santos Garc&#237;a"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "Leonidas"
                "apellidos" => "Cruzado Vega"
              ]
              1 => array:2 [
                "nombre" => "Alba"
                "apellidos" => "Santos Garc&#237;a"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2013251421001085"
          "doi" => "10.1016/j.nefroe.2021.11.003"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251421001085?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699521000230?idApp=UINPBA000064"
      "url" => "/02116995/0000004100000005/v1_202109170826/S0211699521000230/v1_202109170826/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2013251421001176"
    "issn" => "20132514"
    "doi" => "10.1016/j.nefroe.2020.11.014"
    "estado" => "S300"
    "fechaPublicacion" => "2021-09-01"
    "aid" => "854"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Nefrologia &#40;English Version&#41;. 2021;41:603-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Clinical utility of hybrid &#40;SPECT&#47;CT&#41; imaging in calciphylaxis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "603"
          "paginaFinal" => "604"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Utilidad cl&#237;nica de las im&#225;genes h&#237;bridas &#40;SPECT&#47; CT&#41; en la calcifilaxis"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Kamal Kant Sahu, Amos Lal, Ajay Kumar Mishra"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Kamal Kant"
              "apellidos" => "Sahu"
            ]
            1 => array:2 [
              "nombre" => "Amos"
              "apellidos" => "Lal"
            ]
            2 => array:2 [
              "nombre" => "Ajay Kumar"
              "apellidos" => "Mishra"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251421001176?idApp=UINPBA000064"
    "url" => "/20132514/0000004100000005/v1_202112230647/S2013251421001176/v1_202112230647/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2013251421001103"
    "issn" => "20132514"
    "doi" => "10.1016/j.nefroe.2021.11.005"
    "estado" => "S300"
    "fechaPublicacion" => "2021-09-01"
    "aid" => "850"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Nefrologia &#40;English Version&#41;. 2021;41:599-601"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Aplastic anemia associated with parvovirus B19 in living donor kidney transplantation&#58; experience of a reference center"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "599"
          "paginaFinal" => "601"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Anemia apl&#225;sica asociada a parvovirus B19 en trasplante renal de donante vivo&#58; experiencia de un centro de referencia"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2453
              "Ancho" => 3333
              "Tamanyo" => 543806
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical course of the five transplant recipients with a diagnosis of parvovirus B19&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Lorena Noriega-Salas, Jose Cruz-Santiago, Bibiana L&#242;pez-L&#242;pez, Catalina del Rosario Garcia-Ramirez, Arlette Robledo-Melendez"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Lorena"
              "apellidos" => "Noriega-Salas"
            ]
            1 => array:2 [
              "nombre" => "Jose"
              "apellidos" => "Cruz-Santiago"
            ]
            2 => array:2 [
              "nombre" => "Bibiana"
              "apellidos" => "L&#242;pez-L&#242;pez"
            ]
            3 => array:2 [
              "nombre" => "Catalina"
              "apellidos" => "del Rosario Garcia-Ramirez"
            ]
            4 => array:2 [
              "nombre" => "Arlette"
              "apellidos" => "Robledo-Melendez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0211699521000485"
        "doi" => "10.1016/j.nefro.2020.11.016"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699521000485?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251421001103?idApp=UINPBA000064"
    "url" => "/20132514/0000004100000005/v1_202112230647/S2013251421001103/v1_202112230647/en/main.assets"
  ]
  "en" => array:16 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letters to the Editor</span>"
    "titulo" => "Single rituximab dose as treatment for membranoproliferative glomerulonephritis relapse after kidney transplant"
    "tieneTextoCompleto" => true
    "saludo" => "Dear Editor&#44;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "601"
        "paginaFinal" => "603"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Leonidas Cruzado Vega, Alba Santos Garc&#237;a"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Leonidas"
            "apellidos" => "Cruzado Vega"
            "email" => array:1 [
              0 => "leocruzadov@hotmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "Alba"
            "apellidos" => "Santos Garc&#237;a"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Hospital General Universitario de Elche&#44; Alicante&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Dosis &#250;nica de rituximab como tratamiento de recidiva de glomerulonefritis membranoproliferativa en trasplante renal"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1786
            "Ancho" => 2833
            "Tamanyo" => 232536
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Changes over time in proteinuria and plasma albumin&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The current classification of membranoproliferative glomerulonephritis &#40;MPGN&#41; is based on immunofluorescence findings&#44; with aetiological and therapeutic implications&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Idiopathic MPGN is uncommon&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">2</span></a> Treatment recommendations are therefore based on case series and non-randomised clinical trials&#46; Current therapy consists of corticosteroids and antiproliferative agents &#40;mycophenolate&#44; cyclophosphamide&#41;&#44; monoclonal antibodies &#40;rituximab&#44; bortezomib&#41; or plasmapheresis&#46;<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">3&#8211;5</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Worse kidney graft survival and a higher risk of relapse in kidney transplantation have been demonstrated in patients with MPGN compared to other forms of glomerulonephritis&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">2</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">We report the case of a 66-year-old man with a history of arterial hypertension and diabetes mellitus who&#44; in 2012&#44; developed kidney failure &#40;creatinine 1&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&#44; glomerular filtration rate &#91;GFR&#93; 50<span class="elsevierStyleHsp" style=""></span>ml&#47;min&#41; associated with nephrotic syndrome &#40;proteinuria &#62;15<span class="elsevierStyleHsp" style=""></span>g&#47;24<span class="elsevierStyleHsp" style=""></span>h&#44; hypoalbuminaemia and dyslipidaemia&#41;&#44; with microscopic haematuria&#44; without casts&#46; The initial workup included antineutrophil cytoplasmic antibodies &#40;ANCAs&#41;&#44; antinuclear antibodies &#40;ANAs&#41;&#44; rheumatoid factor&#44; protein electrophoresis in serum and urine &#40;negative&#44; normal C3 and C4&#41;&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">The results of a kidney biopsy were consistent with type 1 MPGN&#46; Immunofluorescence showed deposits of immunoglobulin G &#40;IgG&#41; &#40;3&#43;&#41;&#44; C3 &#40;3&#43;&#41; and immunoglobulin M &#40;IgM&#41; &#40;&#43;&#41; in the mesangium and capillary walls&#46; Neoplasms and infections were ruled out as causes of glomerular injury &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">Treatment was started with angiotensin-converting enzyme &#40;ACE&#41; inhibitors plus mycophenolate and steroids&#44; with no response after three months&#46; Given the patient&#39;s progressive decline in kidney function&#44; a decision was made to switch to oral cyclophosphamide plus steroids&#46; This treatment was suspended after four months due to lack of response&#46; In 2014&#44; the patient started peritoneal dialysis&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">In 2016&#44; he received his first kidney graft from a cadaver donor&#44; with five human leukocyte antigen &#40;HLA&#41; incompatibilities&#46; Induction therapy was administered with thymoglobulin &#40;6<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#41;&#44; mycophenolate&#44; prednisone and tacrolimus&#46; In the post-transplantation period&#44; he showed slow recovery of kidney function with creatinine levels of up to 1<span class="elsevierStyleHsp" style=""></span>mg&#47;dl &#40;GFR<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>70<span class="elsevierStyleHsp" style=""></span>ml&#47;min&#41; and proteinuria levels around 1&#46;5<span class="elsevierStyleHsp" style=""></span>g&#47;24<span class="elsevierStyleHsp" style=""></span>h&#44; on treatment with ACE inhibitors&#46; Three months after transplantation&#44; he presented cytomegalovirus infection&#44; which was treated with valganciclovir with a good response&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Six months after transplantation&#44; the patient presented nephrotic syndrome of new onset&#44; with proteinuria levels of 12 g&#47;day and hypoalbuminaemia&#44; with stable kidney function&#46; An immunology workup and HLA antibodies were negative&#46; The results of a kidney graft biopsy were consistent with immune complex-mediated diffuse endocapillary proliferative glomerulonephritis and C3 deposits&#46; Immunofluorescence showed IgG &#40;3&#43;&#41; and C3 &#40;2&#43;&#41; with a diffuse subepithelial and mesangial granular pattern&#46; The C4d antibody was negative&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">To treat MPGN recurrence&#44; the patient&#39;s initial therapy included increasing mycophenolate to a dose of 2<span class="elsevierStyleHsp" style=""></span>g&#47;day and increasing prednisone to a dose of 50<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#46; He presented moderate cytomegalovirus viral load reactivation&#46; Despite treatment&#44; his nephrotic syndrome did not improve&#44; reaching proteinuria levels as high as 17<span class="elsevierStyleHsp" style=""></span>g&#47;24<span class="elsevierStyleHsp" style=""></span>h and serum albumin concentration of 2<span class="elsevierStyleHsp" style=""></span>g&#47;dl&#46; Changes over time in proteinuria and plasma albumin following transplantation are shown in <a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">Given that the prior cycle of cyclophosphamide had no response&#44; a decision was made to administer treatment with rituximab &#40;375<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#41;&#46; He received a dose of 1<span class="elsevierStyleHsp" style=""></span>g&#44; with no complications&#46; His CD19 lymphocyte levels&#44; monitored every three months&#44; were suppressed during the first year&#46; After starting rituximab&#44; the patient showed gradual resolution of proteinuria as of the first month&#44; and after one year his nephrotic syndrome resolved&#46; As of 2019&#44; he has developed skin spinocellular and squamous cell carcinoma&#59; consequently&#44; he has been switched from mycophenolate to a mammalian target of rapamycin &#40;m-TOR&#41; inhibitor and his tacrolimus dose has been reduced&#44; with no repercussions on his proteinuria&#46; Two years after treatment with rituximab&#44; his proteinuria has continued to drop &#40;&#60;1<span class="elsevierStyleHsp" style=""></span>g&#47;day&#41; and his kidney function is stable&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">Post-transplant MPGN recurrence is very common&#59; some series have reported rates as high as 50&#37; in the first 24 months&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">6</span></a> At present&#44; the optimum treatment for recurrence is not clear&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">Rituximab &#40;an anti-CD20 monoclonal antibody&#41; has been used in case series&#44; achieving complete or partial remission&#44; although its dosing remains unclear&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">7</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">Other authors have used bortezomib in cases of MPGN with kappa chain deposits&#44; with no prior diagnosis of dysproteinaemia&#44; with a good clinical response&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">8</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">In our case&#44; a single dose of 1<span class="elsevierStyleHsp" style=""></span>g was administered with regular monitoring of CD19 lymphocyte levels&#46; As they remained reduced for up to approximately one year&#44; no new doses were proposed&#46; In conclusion&#44; in our case&#44; rituximab was effective in achieving remission of post-transplant recurrent MPGN&#46; Complete response to treatment with rituximab is not immediate&#44; with effects beyond one year following administration&#46; Monitoring of CD19 lymphocyte levels may be useful to minimise the dose taken&#44; and is particularly useful in transplant recipients given the cumulative immunosuppression load with the onset of undesirable effects&#44; such as tumours and infections&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of interest</span><p id="par0090" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:2 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Conflicts of interest"
        ]
        1 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Cruzado Vega L&#44; Santos Garc&#237;a A&#46;&#44; Dosis &#250;nica de rituximab como tratamiento de recidiva de glomerulonefritis membranoproliferativa en trasplante renal&#46; Nefrologia&#46; 2021&#59;41&#58;601&#8211;603&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1786
            "Ancho" => 2833
            "Tamanyo" => 232536
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Changes over time in proteinuria and plasma albumin&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:8 [
            0 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "C3 glomerulopathy&#58; consensus report"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;C&#46; Pickering"
                            1 => "V&#46;D&#46; D&#769;Agati"
                            2 => "C&#46;M&#46; Nester"
                            3 => "R&#46;J&#46; Smith"
                            4 => "M&#46; Haas"
                            5 => "G&#46;B&#46; Appel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ki.2013.377"
                      "Revista" => array:6 [
                        "tituloSerie" => "Kidney Int"
                        "fecha" => "2013"
                        "volumen" => "84"
                        "paginaInicial" => "1079"
                        "paginaFinal" => "1089"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24172683"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis&#58; an ANZDATA registry study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;J&#46; Wilson"
                            1 => "Y&#46; Cho"
                            2 => "A&#46; Texeira-Pinto"
                            3 => "N&#46; Isbel"
                            4 => "S&#46; Campbell"
                            5 => "C&#46; Hawley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "BCM Nephrol"
                        "fecha" => "2019"
                        "volumen" => "20"
                        "paginaInicial" => "417"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "C3 glomerulopathy and MPGN &#8211; current classification"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "B&#46; Hohenstein"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Dtsch Med Wochenschr"
                        "fecha" => "2020"
                        "volumen" => "145"
                        "paginaInicial" => "232"
                        "paginaFinal" => "239"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness of pulse cyclophosphamide plus oral steroid therapy in idiopathic membranoproliferative glomerulonephritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "H&#46; T&#246;z"
                            1 => "E&#46; Ok"
                            2 => "A&#46; Unsal"
                            3 => "G&#46; A&#351;&#231;i"
                            4 => "Ba&#351;demirF G&#46;"
                            5 => "A&#46; Ba&#351;&#231;i"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Nefrol Dial Transplant"
                        "fecha" => "1997"
                        "volumen" => "12"
                        "paginaInicial" => "1081"
                        "paginaFinal" => "1082"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Yuan"
                            1 => "J&#46; Zou"
                            2 => "X&#46; Zhang"
                            3 => "H&#46; Liu"
                            4 => "J&#46; Teng"
                            5 => "Y&#46; Zhong"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.5414/cnp73354"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Nephrol"
                        "fecha" => "2010"
                        "volumen" => "73"
                        "paginaInicial" => "354"
                        "paginaFinal" => "359"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20420795"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Recurrent and de novo glomerulonephritis after kidney transplantation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "W&#46;H&#46; Lim"
                            1 => "M&#46; Shingde"
                            2 => "G&#46; Wong"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fimmu.2019.01944"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Immunol"
                        "fecha" => "2019"
                        "volumen" => "10"
                        "paginaInicial" => "1944"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31475005"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Recurrent glomerulonephritis after kidney transplantation&#58; risk factors and allograft outcomes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46;J&#46; Allen"
                            1 => "S&#46;J&#46; Chadban"
                            2 => "J&#46;C&#46; Craig"
                            3 => "W&#46;H&#46; Lim"
                            4 => "R&#46;D&#46;M&#46; Allen"
                            5 => "P&#46;A&#46; Clayton"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.kint.2017.03.015"
                      "Revista" => array:6 [
                        "tituloSerie" => "Kidney Int"
                        "fecha" => "2017"
                        "volumen" => "92"
                        "paginaInicial" => "461"
                        "paginaFinal" => "469"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28601198"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits &#40;PGNMIGD&#41; following rituximab treatment in renal allograft"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "J&#46; Von Visger"
                            1 => "C&#46; Cassol"
                            2 => "U&#46; Nori"
                            3 => "G&#46; Franco-Ahumada"
                            4 => "T&#46; Nadasdy"
                            5 => "A&#46;A&#46; Satoskar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "BCM Nephrol"
                        "fecha" => "2019"
                        "volumen" => "20"
                        "paginaInicial" => "53"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000004100000005/v1_202112230647/S2013251421001085/v1_202112230647/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35436"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Letters to the Editor"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000004100000005/v1_202112230647/S2013251421001085/v1_202112230647/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251421001085?idApp=UINPBA000064"
]
Share
Journal Information
Vol. 41. Issue. 5.September - October 2021
Pages 489-604
Vol. 41. Issue. 5.September - October 2021
Pages 489-604
Letters to the Editor
Open Access
Single rituximab dose as treatment for membranoproliferative glomerulonephritis relapse after kidney transplant
Dosis única de rituximab como tratamiento de recidiva de glomerulonefritis membranoproliferativa en trasplante renal
Visits
3964
Leonidas Cruzado Vega
Corresponding author
leocruzadov@hotmail.com

Corresponding author.
, Alba Santos García
Hospital General Universitario de Elche, Alicante, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
Dear Editor,

The current classification of membranoproliferative glomerulonephritis (MPGN) is based on immunofluorescence findings, with aetiological and therapeutic implications.1

Idiopathic MPGN is uncommon.2 Treatment recommendations are therefore based on case series and non-randomised clinical trials. Current therapy consists of corticosteroids and antiproliferative agents (mycophenolate, cyclophosphamide), monoclonal antibodies (rituximab, bortezomib) or plasmapheresis.3–5

Worse kidney graft survival and a higher risk of relapse in kidney transplantation have been demonstrated in patients with MPGN compared to other forms of glomerulonephritis.2

We report the case of a 66-year-old man with a history of arterial hypertension and diabetes mellitus who, in 2012, developed kidney failure (creatinine 1.5mg/dl, glomerular filtration rate [GFR] 50ml/min) associated with nephrotic syndrome (proteinuria >15g/24h, hypoalbuminaemia and dyslipidaemia), with microscopic haematuria, without casts. The initial workup included antineutrophil cytoplasmic antibodies (ANCAs), antinuclear antibodies (ANAs), rheumatoid factor, protein electrophoresis in serum and urine (negative, normal C3 and C4).

The results of a kidney biopsy were consistent with type 1 MPGN. Immunofluorescence showed deposits of immunoglobulin G (IgG) (3+), C3 (3+) and immunoglobulin M (IgM) (+) in the mesangium and capillary walls. Neoplasms and infections were ruled out as causes of glomerular injury (Fig. 1).

Fig. 1.

Changes over time in proteinuria and plasma albumin.

(0.22MB).

Treatment was started with angiotensin-converting enzyme (ACE) inhibitors plus mycophenolate and steroids, with no response after three months. Given the patient's progressive decline in kidney function, a decision was made to switch to oral cyclophosphamide plus steroids. This treatment was suspended after four months due to lack of response. In 2014, the patient started peritoneal dialysis.

In 2016, he received his first kidney graft from a cadaver donor, with five human leukocyte antigen (HLA) incompatibilities. Induction therapy was administered with thymoglobulin (6mg/kg), mycophenolate, prednisone and tacrolimus. In the post-transplantation period, he showed slow recovery of kidney function with creatinine levels of up to 1mg/dl (GFR>70ml/min) and proteinuria levels around 1.5g/24h, on treatment with ACE inhibitors. Three months after transplantation, he presented cytomegalovirus infection, which was treated with valganciclovir with a good response.

Six months after transplantation, the patient presented nephrotic syndrome of new onset, with proteinuria levels of 12 g/day and hypoalbuminaemia, with stable kidney function. An immunology workup and HLA antibodies were negative. The results of a kidney graft biopsy were consistent with immune complex-mediated diffuse endocapillary proliferative glomerulonephritis and C3 deposits. Immunofluorescence showed IgG (3+) and C3 (2+) with a diffuse subepithelial and mesangial granular pattern. The C4d antibody was negative.

To treat MPGN recurrence, the patient's initial therapy included increasing mycophenolate to a dose of 2g/day and increasing prednisone to a dose of 50mg/day. He presented moderate cytomegalovirus viral load reactivation. Despite treatment, his nephrotic syndrome did not improve, reaching proteinuria levels as high as 17g/24h and serum albumin concentration of 2g/dl. Changes over time in proteinuria and plasma albumin following transplantation are shown in Fig. 1.

Given that the prior cycle of cyclophosphamide had no response, a decision was made to administer treatment with rituximab (375mg/m2). He received a dose of 1g, with no complications. His CD19 lymphocyte levels, monitored every three months, were suppressed during the first year. After starting rituximab, the patient showed gradual resolution of proteinuria as of the first month, and after one year his nephrotic syndrome resolved. As of 2019, he has developed skin spinocellular and squamous cell carcinoma; consequently, he has been switched from mycophenolate to a mammalian target of rapamycin (m-TOR) inhibitor and his tacrolimus dose has been reduced, with no repercussions on his proteinuria. Two years after treatment with rituximab, his proteinuria has continued to drop (<1g/day) and his kidney function is stable.

Post-transplant MPGN recurrence is very common; some series have reported rates as high as 50% in the first 24 months.6 At present, the optimum treatment for recurrence is not clear.

Rituximab (an anti-CD20 monoclonal antibody) has been used in case series, achieving complete or partial remission, although its dosing remains unclear.7

Other authors have used bortezomib in cases of MPGN with kappa chain deposits, with no prior diagnosis of dysproteinaemia, with a good clinical response.8

In our case, a single dose of 1g was administered with regular monitoring of CD19 lymphocyte levels. As they remained reduced for up to approximately one year, no new doses were proposed. In conclusion, in our case, rituximab was effective in achieving remission of post-transplant recurrent MPGN. Complete response to treatment with rituximab is not immediate, with effects beyond one year following administration. Monitoring of CD19 lymphocyte levels may be useful to minimise the dose taken, and is particularly useful in transplant recipients given the cumulative immunosuppression load with the onset of undesirable effects, such as tumours and infections.

Conflicts of interest

The authors have no conflicts of interest to declare.

References
[1]
M.C. Pickering, V.D. D́Agati, C.M. Nester, R.J. Smith, M. Haas, G.B. Appel, et al.
C3 glomerulopathy: consensus report.
Kidney Int, 84 (2013), pp. 1079-1089
[2]
G.J. Wilson, Y. Cho, A. Texeira-Pinto, N. Isbel, S. Campbell, C. Hawley, et al.
Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study.
BCM Nephrol, 20 (2019), pp. 417
[3]
B. Hohenstein.
C3 glomerulopathy and MPGN – current classification.
Dtsch Med Wochenschr, 145 (2020), pp. 232-239
[4]
H. Töz, E. Ok, A. Unsal, G. Aşçi, BaşdemirF G., A. Başçi.
Effectiveness of pulse cyclophosphamide plus oral steroid therapy in idiopathic membranoproliferative glomerulonephritis.
Nefrol Dial Transplant, 12 (1997), pp. 1081-1082
[5]
M. Yuan, J. Zou, X. Zhang, H. Liu, J. Teng, Y. Zhong, et al.
Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis.
Clin Nephrol, 73 (2010), pp. 354-359
[6]
W.H. Lim, M. Shingde, G. Wong.
Recurrent and de novo glomerulonephritis after kidney transplantation.
Front Immunol, 10 (2019), pp. 1944
[7]
P.J. Allen, S.J. Chadban, J.C. Craig, W.H. Lim, R.D.M. Allen, P.A. Clayton, et al.
Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes.
Kidney Int, 92 (2017), pp. 461-469
[8]
J. Von Visger, C. Cassol, U. Nori, G. Franco-Ahumada, T. Nadasdy, A.A. Satoskar.
Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.
BCM Nephrol, 20 (2019), pp. 53

Please cite this article as: Cruzado Vega L, Santos García A., Dosis única de rituximab como tratamiento de recidiva de glomerulonefritis membranoproliferativa en trasplante renal. Nefrologia. 2021;41:601–603.

Copyright © 2021. Sociedad Española de Nefrología
Download PDF
Idiomas
Nefrología (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?